Abstract
A BRAF somatic mutation at residue 600 of the BRAF protein (BRAFV600E) is highly prevalent in papillary thyroid carcinomas (PTC). This mutation occurs in approximately 44% (from 29% to 83%) of PTC depending on the different studies. BRAFV600E is almost always found in PTC with a papillary or a mixed follicular/papillary architecture, being rarer in other subtypes of PTC. The discovery of the BRAFV600E mutation in tissue and fine-needle aspiration (FNA) is diagnostic for PTC and has been frequently associated with worse clinical prognosis. However, some studies failed to reveal this prognostic association. Transcriptional and post-transcriptional modulation of PTC with a BRAF mutation has been evaluated in some recent studies. Current therapeutic approaches targeting BRAF are being tested in clinical trials, particularly in more aggressive PTC. In this review, we will first discuss the diagnostic value of a BRAF mutation for PTC diagnosis. The prognostic role of a BRAFV600E mutation is then outlined and discussed in the context of other well-accepted clinicopathological prognostic parameters for PTC (age, gender, pTNM stage, histological subtype). Finally, the currently and potentially used treatments targeting BRAF in patients with PTC are presented.
Keywords: Papillary thyroid carcinoma, BRAF, mutation, prognosis, diagnostic, theragnostic
Current Medicinal Chemistry
Title: Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications
Volume: 17 Issue: 17
Author(s): Sandra Lassalle, Veronique Hofman, Marius Ilie, Catherine Butori, Alexandre Bozec, Jose Santini, Philippe Vielh and Paul Hofman
Affiliation:
Keywords: Papillary thyroid carcinoma, BRAF, mutation, prognosis, diagnostic, theragnostic
Abstract: A BRAF somatic mutation at residue 600 of the BRAF protein (BRAFV600E) is highly prevalent in papillary thyroid carcinomas (PTC). This mutation occurs in approximately 44% (from 29% to 83%) of PTC depending on the different studies. BRAFV600E is almost always found in PTC with a papillary or a mixed follicular/papillary architecture, being rarer in other subtypes of PTC. The discovery of the BRAFV600E mutation in tissue and fine-needle aspiration (FNA) is diagnostic for PTC and has been frequently associated with worse clinical prognosis. However, some studies failed to reveal this prognostic association. Transcriptional and post-transcriptional modulation of PTC with a BRAF mutation has been evaluated in some recent studies. Current therapeutic approaches targeting BRAF are being tested in clinical trials, particularly in more aggressive PTC. In this review, we will first discuss the diagnostic value of a BRAF mutation for PTC diagnosis. The prognostic role of a BRAFV600E mutation is then outlined and discussed in the context of other well-accepted clinicopathological prognostic parameters for PTC (age, gender, pTNM stage, histological subtype). Finally, the currently and potentially used treatments targeting BRAF in patients with PTC are presented.
Export Options
About this article
Cite this article as:
Lassalle Sandra, Hofman Veronique, Ilie Marius, Butori Catherine, Bozec Alexandre, Santini Jose, Vielh Philippe and Hofman Paul, Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications, Current Medicinal Chemistry 2010; 17 (17) . https://dx.doi.org/10.2174/092986710791111189
DOI https://dx.doi.org/10.2174/092986710791111189 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Hyperglycaemia and Vitamin D: A Systematic Overview
Current Diabetes Reviews The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts
Current Genomics Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Genetic Markers of Osteoarthritis
Current Rheumatology Reviews Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results
Current Radiopharmaceuticals Progesterone Receptor Membrane Component 1 and its Accomplice: Emerging Therapeutic Targets in Lung Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy Effects of 900MHz Mobile Phone Radiation on Human Thyroid Hormone Levels
Recent Patents on Biomarkers CB 1954: From the Walker Tumor to NQO2 and VDEPT
Current Pharmaceutical Design Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging